Abstracts tagged "skin"

Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 1643 • ACR Convergence 2024
Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts
Helen Jarnagin¹, Dillon Popovich², Rezvan Parvizi³, Rosemary Gedert⁴, Lam C. Tsoi⁵, Rachael Wasikowski⁵, Zhiyun Gong¹, Madeline Morrisson⁶, Laurent Perreard⁷, Fred Kolling IV⁷, Dinesh Khanna⁴, Johann Gudjonsson⁴ and Michael Whitfield³, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, West Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴University of Michigan, Ann Arbor, MI, ⁵Michigan, Dept. of Dermatology, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁷Geisel School of Medicine, Dartmouth College, Lebanon
Background/Purpose: We generated a vertically integrated dataset on treatment naïve patients with dcSSc (diffuse Systemic Sclerosis) skin that includes bulk RNA-seq, single nuclei multiome, and…
Abstract Number: 2318 • ACR Convergence 2024
Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
Fadi Kharouf¹, Pankti Mehta², Shangyi Gao², Daniel Pereira³, Richard Cook⁴, Dafna Gladman⁵ and Vinod Chandran⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis typically precedes psoriatic arthritis (PsA), with a variable transition period. In this study, we aimed to explore whether the time interval between the…
Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Ivanna Romankevych¹, Nora Singer², Kaliyani Marathe³, Angela Merritt¹, Ekemini Ogbu⁴, Chen Chen⁵, Megan Quinlan-Waters¹, Kathleen Pelletier⁶, Haihong Shi⁶, Xiaoxing Wang⁶, Bin Huang⁷ and hermine brunner⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cin, OH, ⁶Pfizer Inc, Groton, CT, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…
Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Louise Nielung¹, Merete Hetland², Lone Skov³, Hans Albert Frandsen⁴, Lene Dreyer⁵ and Bente Glintborg⁶, ¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, ⁴Patient Partner, Frederiksberg, Denmark, ⁵Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, ⁶DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
Abstract Number: 2320 • ACR Convergence 2024
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
Eduardo Briones-García¹, Tatiana Sofía Rodríguez-Reyna², Eduardo Martin Nares², Guillermo A Guaracha-Basañez³ and Iris Paola García Herrera⁴, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The utility of nailfold videocapillaroscopy (NVC) in conditions such as systemic sclerosis and primary Raynaud´s phenomenon is well known. Whether patients with psoriatic disease…
Abstract Number: 0786 • ACR Convergence 2024
First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy
Janina Auth¹, Manoj Kumar Selvaraju², Fabian Müller³, Pooja Gupta², Arif Ekici⁴, Carlo Tur¹, Maria Gabriella Raimondo¹, Jörg Distler⁵, Clara Dees⁶, Sara Chenguiti⁶, Melanie Hagen¹, Andreas Wirsching¹, Jule Taubmann⁷, Soraya Kharboutli⁸, Silvia Spoerl⁸, Michael Aigner⁸, Sascha Kretschmann⁸, Ingrid Vasova⁸, Andreas MAckensen⁹, Georg Schett¹⁰ and Christina Bergmann¹¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²CUBiDA Department (Core Unit Bioinformatics and Data Analysis), UKER and FAU, Erlangen, Germany, ³Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁴Core Unit Next Generation Sequencing, Erlangen, Germany, ⁵Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁶Department Internal Medicine III, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹⁰Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹¹Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany
Background/Purpose: CD19-targeting CAR T cells showed remarkable improvements of modified Rodnan skin score in SSc patients within 6 months after treatment and stable reduction afterwards…
Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 2348 • ACR Convergence 2024
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Diamant Thaçi¹, Luis Puig², Joseph F. Merola³, Denis Jullien⁴, Antonio Costanzo⁵, Maggie Wang⁶, Delphine Deherder⁷, José M. López Pinto⁸ and Mark Lebwohl⁹, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ²Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ³UT Southwestern Medical Center, Dallas, TX, ⁴Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, ⁵Department of Dermatology, Humanitas Clinical and Research Centre, IRCCS, Rozzano, Milan, Italy, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Braine-l'Alleud, Belgium, ⁸UCB Pharma, Madrid, Spain, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Clinical improvements through Week 152, with no unexpected safety findings, were previously reported with bimekizumab (BKZ) in the BE SURE phase 3 trial and…
Abstract Number: 1528 • ACR Convergence 2023
Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
Francesco Bonomi¹, Arianna Damiani¹, Carmela Coccia¹, Juela Levani¹, elisa Fiorentini², silvia peretti¹, Gemma Lepri¹, martina orlandi¹, francesca bartoli¹, marco Matucci Cerinic³, silvia bellando randone¹ and serena guiducci¹, ¹Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ²Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, ³Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy
Background/Purpose: Treatment of systemic sclerosis (SSc) is challenging, and in the last 2 decades there has been an increasing interest for immunoglobulin (Igs) treatment as…
Abstract Number: 1586 • ACR Convergence 2023
Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing
Zachary Peters¹, Lindsay Mendyka², Sicong Shan¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We…
Abstract Number: 1599 • ACR Convergence 2023
Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus
Mitra Maz¹, Feiyang Ma², Mehrnaz Gharaee-Kermani², Amanda Victory², Amy Hurst², Johann E. Gudjonsson² and J. Michelle Kahlenberg², ¹University of Michigan Medical School, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms…
Abstract Number: 2364 • ACR Convergence 2023
Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis
Monica Yang¹, Seoyeon Lee², Lisa Hazelwood³, Dean Sheppard¹, Francesco Boin⁴ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³AbbVie, Inc., North Chicago, IL, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
Abstract Number: 0254 • ACR Convergence 2023
Microvascular and Cutaneous Assessment in Adult Patients with Hypermobile Ehlers-Danlos Syndrome
Alberto Sulli¹, Francesca Lalli², Elvis Hysa², Andrea Cere¹, Alessandro Pinelli², Silvia Sammorì¹, Emanuele Gotelli¹, Carmen Pizzorni¹, Marco Castori³, Fransiska Malfait⁴, Vanessa Smith⁵ and Maurizio Cutolo⁶, ¹Laboratory of Experimental Rheumatology and Academic Division of Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy, ⁴Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium, ⁵Ghent University Hospital, Gent, Belgium, ⁶Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: Hypermobile Ehlers-Danlos syndrome (hEDS) is a hereditary connective tissue disease characterized by joint hypermobility, chronic musculoskeletal pain, and systemic manifestations, primarily caused by defects…
Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Hung Vo¹, Aarohi Mehendale², Anahita Pilvar³, Eugene Kissin⁴, Marcin Trojanowski⁵, Michael York⁶, Darren Roblyer² and Andreea Bujor⁶, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Department of Electrical and Computer Engineering, Boston University, Boston, MA, ⁴Boston University, Newton, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].